Unicycive(US:UNCY) Globenewswireยท2025-09-21 12:16Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Unicycive between March 29, 2024, and June 27, 2025, to contact them for legal options [1]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA due to the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].